



Contemporary Uses of Erythropoietin in Pregnancy: A Literature Review

Dr. V. Hemavathy 1st , Dr. Sathiyalatha sarathy 2nd , S. Meenaloshini 3rd

M.SC(N), MA, M. phil, Phd 1st , M.SC(N), Phd 2nd , M.SC(N)3rd

Principal 1st , HOD, Department of Obstetrics and Gynaecology 2nd , MSc. Nursing 3rd ,

Sree Balaji College of Nursing, No 7, works Road, Chennai, Tamilnadu, India

Abstract

Erythropoietin (EPO) is a hormone produced by the kidney. Erythropoietin promotes the formation of red blood cells by the bone marrow. The erythropoietin hormone level can be detected and measured in the blood (the EPO test). Measurement of the blood erythropoietin level can be used to detect certain medical conditions. Erythropoietin can be synthesized and used as a treatment of some forms of anemia. Haematopoietin or haemopoietin, it is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood. The primary role of erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Renal blood flow and glomerular filtration increase by 30-50%, and because erythropoietin is of renal origin, EPO concentration has been proved to increase 2-4-folds in the course of pregnancy and plateau is achieved after 20 weeks during the second trimester of pregnancy.

Key words: Erythropoietin , pregnancy

INTRODUCTION

Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow. production predominates in the fetal and perinatal period; renal production is predominant during adulthood. In addition to erythropoiesis, erythropoietin also has other known biological functions. For example, it plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process .Exogenous erythropoietin is produced by recombinant DNA technology in cell culture. Several different pharmaceutical agents are available with a variety of glycosylation patterns, and are

collectively called erythropoiesis-stimulating agents (ESA). The specific details for labeled use vary between the package inserts, but ESAs have been used in the treatment of anaemia in chronic kidney disease, anaemia in myelodysplasia, and in anaemia from cancer chemotherapy. Boxed warnings include a risk of death, myocardial infarction, stroke, venous thromboembolism, and tumour recurrence. Exogenous erythropoietin has been used illicitly as a performance-enhancing drug; it can often be detected in blood, due to slight differences from the endogenous protein, for example, in features of post-translational modification. Function of Erythropoietin

Red blood cell production

The primary role of erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis. Erythropoietin is the primary erythropoietic factor that cooperates with various other growth factors (e.g., IL-3, IL-6, glucocorticoids, and SCF) involved in the development of erythroid lineage from multipotent progenitors. The burst-forming unit-cells start erythropoietin receptor expression and are sensitive to erythropoietin. Subsequent stage, the colony-forming unit-erythroid (CFU-E), expresses maximal erythropoietin receptor density and is completely dependent on erythropoietin for further differentiation. Precursors of red cells, the proerythroblasts and basophilic erythroblasts, also express erythropoietin receptor and are therefore affected by it. Non haematopoietic roles of erythropoietin.

Mechanism of action

Erythropoietin has been shown to exert its effects by binding to the erythropoietin receptor (EpoR). EPO is highly glycosylated (40% of total molecular weight), with half-life in blood around five hours. EPO's half-life may vary between endogenous and various recombinant versions. Additional glycosylation or other alterations of EPO via recombinant technology have led to the increase of EPO's stability in blood (thus requiring less frequent injections). EPO binds to the erythropoietin receptor on the red cell progenitor surface and activates a JAK2 signaling cascade. Erythropoietin receptor expression is found in a number of tissues, such as bone marrow and peripheral/central nervous tissue. In the bloodstream, red cells themselves do not express erythropoietin receptor, so cannot respond to EPO. However, indirect dependence of red cell longevity in the blood on plasma erythropoietin levels has been reported, a process termed neocytolysis.

Synthesis and regulation

Erythropoietin levels in blood are quite low in the absence of anaemia, at around 10mU/ml. However, in hypoxic stress, EPO production may increase 1000-fold, reaching 10,000mU/ml of blood. EPO is produced mainly by interstitial cells in the peritubular capillary bed [9] of the renal cortex. It is synthesized by renal peritubular cells in adults, with a small amount being produced in the liver. Regulation is believed to rely on

a feedback mechanism measuring blood oxygenation. Constitutively synthesized transcription factors for EPO, known as hypoxia-inducible factors, are hydroxylated and proteosomally digested in the presence of oxygen.

Erythropoietin concentration in Normal and Complicated Pregnancy

Changes in circulatory system during pregnancy affect renal function, due to physiological increase in blood volume.

Renal blood flow and glomerular filtration

Renal blood flow and glomerular filtration increase by 30-50%, and because erythropoietin is of renal origin, EPO concentration has been proved to increase 2-4-folds in the course of pregnancy [14-17] and plateau is achieved after 20 weeks during the second trimester of pregnancy. It is believed that physiological blood dilution in pregnancy, increase in renal oxygen consumption due to intensified glomerular filtration as well as paracrine and autocrine mechanisms are likely to be responsible for increased EPO renal secretion in pregnancy.

stated that some authors found no correlation between EPO and haemoglobin concentration in women with normal pregnancy in the first or second trimester. noticed that pregnant women have significantly lower serum erythropoietin level compared to healthy pregnant patients. It

was also found that EPO concentration in cord blood of new born babies born by mothers with anaemia is significantly higher than in healthy women's babies. Factually anaemia in pregnancy causes increased EPO secretion as a response to low haemoglobin concentration and ferritin deficiency. Acute and chronic bleedings in pregnancy as well as multiple pregnancies are associated with patient's elevated blood serum EPO concentration. The link between increased blood serum. EPO concentration in pregnant women and the occurrence of preeclampsia is controversial. There are various theories explaining the correlation. One hypothesis assumes the elevated EPO concentration in the blood of patients with preeclampsia is caused by reduced renal perfusion, which results in local relative hypoxia and compensatory increase of renal EPO secretion.

Increased blood serum

EPO concentration in these women results from reduced placental blood flow and its reduced oxygenation, which induces compensatory local EPO secretion by placenta. This mechanism is supposed to increase total EPO pool in blood serum of pregnant patients with preeclampsia. Patients with preeclampsia had statistically insignificant increase in EPO concentration compared to healthy pregnant women. Additionally, no differences were found in the level of haemoglobin and haematocrit .

EPO was higher in pregnant women with preeclampsia than in healthy pregnant women, however statistically insignificant. But they found blood serum EPO concentration to negatively correlate with haematocrit value

and haemoglobin concentration. Use of erythropoietin stimulating agents for the treatment of anaemia in pregnant women The most common true anaemias during pregnancy are iron and/or folate deficiency anaemia, and also congenital anaemias, such as thalassaemia's, may be the most frequent causes of pregnancy anaemia. Haemoglobin H disease which is the intermediate form of alpha thalassaemia is usually associated with an increased severity of anaemia during pregnancy. Haemoglobin level may sometimes fall to 70g/L or even less necessitating blood transfusions to preserve the health of the mother and the developing foetus.

Conclusion

Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. It is a cytokine for precursors in the bone marrow. Also called haematopoietic or haemopoietin, it is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. The primary role of erythropoietin is an essential hormone for red blood cell production. Erythropoietin has its primary effect on red blood cell progenitors and precursors. Changes in circulatory system during pregnancy affect renal function, due to physiological increase in blood volume. Renal blood flow and glomerular filtration increase by 30-50%, and because erythropoietin is of renal origin, EPO concentration has been proved to increase 2-4-folds in the course of pregnancy and plateau is achieved after 20 weeks during the second trimester of pregnancy.

REFERENCES

1. Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. *Proc Natl Aca Sci USA* 98(7): 4044-4049.
2. Haroon ZA, Amin K, Jiang X, Arcasoy MO (2003) A novel role for erythropoietin during fibrin-induced wound-healing response. *Am J Pathol* 163(3): 993-1000.
3. Ashby DR, Gale DP, Busbridge M, Murphy KA, Duncan ND, et al. (2010) Erythropoietin administration in human causes a marked and prolonged reduction in circulating hepcidin. *Haematological* 95(3): 505-508.
4. Marti HH, Gassmann M, Wenger RH, Kvietikova I, Morganti-Kossmann MC, et al. (1997) Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. *Kidney Int* 51(2): 416-418.
5. Miskowiak K, O'Sullivan U, Harmer CJ (2007) Erythropoietin Enhances Hippocampal Response during Memory Retrieval in Humans. *Journal of Neuroscience* 27(11): 2788-2792.
6. Miskowiak KW, Favaron E, Hafizi S, Inkster B, Goodwin GM, et al. (2009) Effects of erythropoietin on emotional processing biases in patients with major depression: An exploratory fMRI study. *Psychopharmacology* 207(1): 133-142.
7. Middleton SA, Barbone FP, Johnson DL, Thurmond RL, You Y, et al. (1999) Shared and unique determinants of the erythropoietin (EPO) receptor are important for binding EPO and EPO mimetic peptide. *J Biol Chem* 274(20): 14163-14169.
8. Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, et al. (1998) An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. *Nature Structural & Molecular Biology* 5(11): 993-1004.

9. Jacobson LO, Goldwasser E, Fried W, Plzak L (1957) Role of the kidney in erythropoiesis. *Nature* 179 (4560): 633-634.
10. Fisher JW, Koury S, Ducey T, Mendel S (1996) Erythropoietin production by interstitial cells of hypoxic monkey kidneys. *British journal of haematology* 95(1): 27-32.
11. Jelkmann W (2007) Erythropoietin after a century of research: younger than ever. *Eur J Haematol* 78(3): 183-205.
12. Kowalska-kanka A, Maciejewski T (2013) The role and regulation of secretion of erythropoietin in pregnancy. *Dev Period Med* 17(3): 270-275.
13. Markwitz W, Oko A, Nerek CW, wysokiegoryzyka CR, Bręborowicz GH (2006) Ośrodek Wydawnictw Naukowych. Poznań pp. 719-728.
14. Conrad KP, Benyo DF, Westerhausen-Larsen A (1996) Expression of erythropoietin by the human placenta. *Faseb J* 10: 760-768.
15. Nangaku M, Eckardt KU (2007) Hypoxia and the HIF system in kidney disease. *J Mol Med (Berl)* 85(12): 1325-1330.

